Selling a medspa or buying one comes with a moving piece most brokers never mention: the medical director and collaborating physician relationship doesn't transfer automatically just because the ownership does.
- A medical director for medspa acquisition deals must be verified, not assumed to transfer with the sale.
- Collaborating physician agreements often lack assignment clauses, leaving buyers uncovered on day one post-close.
- Chart review history and good faith exam records are diligence items buyers should request before signing, not after.
- US Medical Directors recommends auditing physician oversight structure before the letter of intent, not at closing.
Why this matters
A medspa's valuation rests on its ability to keep operating legally the day after close. If the collaborating physician agreement doesn't survive the ownership change, or the buyer inherits a chart review backlog, the deal's real risk sits outside the financials entirely.
Brokers focus on revenue multiples and lease terms. Physician oversight rarely makes the diligence checklist, which is exactly why it causes post-close scrambles in 2026 deals more than almost any other compliance gap. Buyers who skip this step find out the hard way, usually a few weeks after the wire transfer clears, that the practice has no active collaborating physician on file.
Who this is for
This is for medspa owners preparing to sell, private equity groups evaluating a medspa rollup, buyers running diligence on an acquisition target, and brokers who need to know what to ask a seller before a deal moves forward. If you're structuring a multi-location purchase or merging two medspa brands, the oversight questions below apply to every location in the deal, not just the flagship one.
What to look for in a medical director during a sale
1. Does the collaborating physician agreement survive an ownership change
Most collaborating physician agreements are written between the physician and the entity, not the entity's owners, but many still include termination-on-change-of-control language that a buyer will never notice until it's triggered. Check the assignment clause specifically. If the agreement is silent on ownership transfer, treat that as a gap to close before signing, not after.
2. Corporate practice of medicine structure in every state the deal touches
A rollup buying locations in three or four states inherits three or four different corporate practice of medicine frameworks, and what's compliant in one state can be a violation in another. Review the corporate practice of medicine rules for every state in the deal before you sign anything, since a PE-backed buyer restructuring ownership can accidentally trip a rule the seller never had to worry about as a single-location operator.
3. Chart review and documentation trail
Buyers should ask for the last 90 days of chart review records, not a summary — the actual documentation. A seller who can't produce it is either behind on compliance or never had a real chart review process running, and either one is a red flag worth a price adjustment.
4. Good faith exam compliance history
Good faith exams are a state-by-state requirement, and a seller's history of completing them on schedule tells a buyer a lot about how tight the practice's overall compliance posture is. Spotty GFE records are a leading indicator of other oversight gaps.
5. Liability coverage that transfers cleanly
Medical director liability coverage is often tied to the specific entity and physician combination, and a change of ownership can void or complicate it. Confirm in writing that coverage extends through close and beyond, not just up to the signing date.
6. License status for every location and provider
A deal covering multiple locations means multiple state licenses, multiple collaborating physicians in some cases, and multiple renewal dates. Miss one expired license buried in a location's file and the buyer inherits an unlicensed practice on day one.
Where oversight breaks before the ink dries
License verification before signing. The hook here is simple: don't take the seller's word for it. Verify a collaborating physician's license directly with the state board before you sign, because a lapsed or restricted license discovered post-close is far more expensive to fix than a delayed closing date. This applies to every location in a multi-site deal, not just the one with the most revenue. Verdict: Non-negotiable.
Chart review audit as a diligence line item. Sellers who run tight chart review services for medspas can produce documentation on request within days, not weeks. A seller who takes 30 to 90 days to produce basic chart review records — the typical window for medspa deal diligence overall — is signaling how disorganized the underlying operation actually is. Treat the speed of that response as a diligence data point on its own. Verdict: Worth building into every term sheet.
Agreement continuity through closing. A collaborating physician agreement that automatically terminates on change of control needs a bridge plan before the deal closes, whether that's a short-term extension, a new agreement executed at close, or a negotiated assignment. Switching collaborating physicians without disruption is possible, but it needs a plan in place before signing, not a scramble after. Verdict: Handle in the purchase agreement, not after.
Liability coverage restructuring. Buyers acquiring across state lines, especially rollups spanning many states of varying supervision rules, need liability coverage confirmed for each jurisdiction separately. A blanket assumption that coverage "just carries over" is the single most common post-close surprise in medspa acquisitions in 2026. Verdict: Confirm in writing before wire transfer.
What to avoid
- A seller's verbal assurance that "the doctor is fine with the sale." Get it in writing, signed, before closing — verbal assurances don't survive a state board audit.
- Treating one location's compliance as representative of the whole portfolio. Every location needs its own license check, its own chart review file, and its own collaborating physician confirmation.
- Assuming corporate practice of medicine rules are the same across states. They aren't, and a structure that's fine in Texas can be a violation in California or New York.
Get oversight sorted before you close
Verify licensing, chart review, and physician coverage across every location in the deal.
Verdict comparison across the criteria
| Criteria | Why it matters in a sale | Verdict |
|---|---|---|
| Agreement survives ownership change | Deals close, then the collaborating physician relationship can lapse overnight | Non-negotiable |
| Corporate practice of medicine structure | Multi-state deals inherit multiple, conflicting frameworks | Review per state |
| Chart review trail | Signals overall compliance discipline of the seller | Request 90 days minimum |
| Good faith exam history | Predicts other gaps in oversight | Audit before signing |
| Liability coverage transfer | Coverage tied to entity can void on ownership change | Confirm in writing |
| License status per location | One lapsed license means an unlicensed practice post-close | Verify with state board |
FAQ
Does a collaborating physician agreement automatically transfer during a medspa sale?
No, not automatically. Most agreements are entity-specific and many include change-of-control termination language, so buyers need to confirm assignment terms in writing before closing in 2026.
What compliance documents should a buyer request during medspa acquisition diligence?
Buyers should request active collaborating physician agreements, the last 90 days of chart review records, good faith exam logs, and current license status for every provider and location. Missing or incomplete records at this stage usually mean broader gaps.
How long does medical director diligence take during a medspa acquisition?
Diligence on physician oversight typically runs alongside the broader 30- to 90-day due diligence window common in medspa deals. License verification and agreement review can be completed faster if the seller’s records are organized.
Is a medical director required for a medspa in every state?
Requirements vary by state, but the majority of states require some form of physician oversight, collaborating physician agreement, or medical director relationship for aesthetic procedures. Multi-state buyers must check each state separately.
What happens if a medspa’s collaborating physician agreement lapses after an acquisition closes?
A lapsed agreement means the practice may be operating without required medical oversight, which puts licenses, insurance coverage, and the ability to legally perform procedures at risk. This is why agreement continuity needs to be resolved before close, not discovered after.
Should private equity buyers use one medical director across a medspa rollup?
It depends on the states involved and each state’s supervision ratio rules, since one collaborating physician may not legally be able to cover every location in a multi-state rollup. Rollups usually need a structure reviewed state by state rather than a single blanket arrangement.
Who pays for medical director services after a medspa changes ownership?
This is negotiated as part of the purchase agreement and varies by deal, but buyers should confirm whether existing physician arrangements continue at the same terms or need to be renegotiated at close.
One last thing
The detail most buyers miss entirely: a collaborating physician agreement's assignment clause is usually a single paragraph buried near the end of the document, and it's the paragraph that decides whether the practice has legal medical oversight the morning after closing. Read that paragraph before you read the financials.
Related guides
- Audit your collaborating physician agreement for gaps
- How to switch collaborating physicians without disruption
- Medical director oversight for medspa franchise groups
